Latest:
Myeloproliferative Neoplasm Management: Future Directions in Care
Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Stephen Opat, MBBS
Stephen Opat, MBBS, is the director of Clinical Hematology at Monash Health, Monash University; founder and chair of the Australasian Lymphoma and Related Diseases Registry; and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship in Australia.
Latest:
Dr Opat on the Unique Mechanism of Action of Sonrotoclax in R/R CLL
Stephen Opat, MBBS, explains the unique mechanism of action of sonrotoclax and how it differs from venetoclax for the treatment of patients with relapsed/refractory CLL or SLL.
Stephen Stilgenbauer, MD
Latest:
Dr. Stilgenbauer on Activity With Venetoclax in Patients With CLL
Stephen Stilgenbauer, MD, associate professor, Department of Haematology, Oncology, Rheumatology and Infectious Diseases, University of Ulm, Germany, discusses the clinical activity seen with venetoclax in patients with chronic lymphocytic leukemia, according to results of the open-label, single-arm, multicenter M13-982 study.
Stevan A. Gonzalez, MD MS
Latest:
Dr. Gonzalez on Cost-Benefit of Treating Hepatitis C in HCC Patients Before Transplant
Stevan A. Gonzalez, MD MS, clinical assistant professor, department of internal medicine, Texas A&M College of Medicine, medical director of liver transplantation, Simmons Transplant Institute, Baylor All Saints Medical Center, discusses a cost effectiveness analysis of treating hepatitis C patients with hepatocellular carcinoma (HCC) before or after a liver transplant.
Steven A. Rosenberg, MD, PhD
Latest:
Dr. Steven Rosenberg on the Curative Potential of Adoptive Cell Therapy
Steven A. Rosenberg, MD, PhD, chief, Surgery Branch, senior investigator, head, Tumor Immunology Section, National Cancer Institute, explains advancements in adoptive cell therapy for the treatment of melanoma.
Steven Buechler
Latest:
Steven Buechler Discusses EarlyR Gene Signature in the BIG 1-98 Trial for Breast Cancer
Steven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group (BIG) 1-98 study. This randomized, double-blind, phase III trial compared letrozole with tamoxifen as an adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer